2025 annual financial data
Relmada Therapeutics 2025 Net income growth
Direct answer
Net income growth was 28.25%.
Operating income was -59,100,200 USD and net income was -57,385,163 USD.
Operating cash flow was -45,786,988 USD.
Get free Relmada Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Revenue
- 0 USD
- Operating income
- -59,100,200 USD
- Net income
- -57,385,163 USD
- Operating cash flow
- -45,786,988 USD